|
|
|
Hepatitis Clinical Trials, Diagnosis, and Treatment |
|
Thank you for your interest in clinical trials for
Hepatitis.
Please click "Search" to find Hepatitis clinical trials and medical research
studies or read below for information on Hepatitis diagnosis and treatment.
If you receive too many study listings you may enter your zip code to find the
locations closest to you.
|
|
|
|
|
Results from Clinical Connection:
|
|
|
|
Your search returned 6 studies:
|
|
|
|
|
Results from other databases:
|
|
Your search returned over 250 results. The top 250 results are being displayed. Please use additional keywords or decrease the search distance. |
|
Your search returned 250 studies:
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-01107
Conditions: Hepatitis C Location: Springfield, MA
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-10021
Conditions: Hepatitis C Location: New York, NY
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-10065
Conditions: Hepatitis C Location: New York, NY
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-32803
Conditions: Hepatitis C Location: Orlando, FL
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-37205
Conditions: Hepatitis C Location: Nashville, TN
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-74135
Conditions: Hepatitis C Location: Tulsa, OK
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-78215
Conditions: Hepatitis C Location: San Antonio, TX
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-92037
Conditions: Hepatitis C Location: La Jolla, CA
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection - NCT00720434-94115
Conditions: Hepatitis C Location: San Francisco, CA
- A Network & Dyad HIV Prevention Intervention for IDU's - 1 - NCT00218335-21231
Conditions: HIV - Hepatitis Location: Baltimore, MD
- A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-07102
Conditions: HIV Infections - Hepatitis C - HCV Infection Location: Newark, NJ
- A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM3) - NCT00959699-21287
Conditions: HIV Infections - Hepatitis C - HCV Infection Location: Baltimore, MD
- A Phase II Study to Determine the Safety and Efficacy of Interferon-Gamma in Patients With Chronic Hepatitis B - NCT00753467-91105
Conditions: Hepatitis B Location: Pasadena, CA
- A Pilot Study of Siliphos in Adults With Non-Alcoholic Steatohepatitis (NASH) - NCT00443079-92103
Conditions: Fatty Liver Location: San Diego, CA
- A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C - NCT00814606-60637
Conditions: Hepatitis C - Hepatitis C Virus Location: Chicago, IL
- A Randomized Trial of Vaccine Adherence in Young Injection Drug Users - 1 - NCT00244374-94143
Conditions: Adherence - Community Outreach - HIV Risk Behaviors - Hepatitis A Vaccines - Hepatitis B Vaccines - Hepatitis C - Needle-Exchange Programs - Substance Abuse, Intravenous Location: San Francisco, CA
- A Randomized, Controlled Trial of Fluvastatin Added to Pegylated Interferon and Ribavirin (PI+R) Versus PI+R Alone for Treatment of Chronic Hepatitis C Not Previously Treated - NCT00487318-73104
Conditions: Chronic Hepatitis C Location: OKlahoma City, OK
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-02114
Conditions: Hepatitis C, Chronic Location: Boston, MA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-07601
Conditions: Hepatitis C, Chronic Location: Hackensack, NJ
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-08234
Conditions: Hepatitis C, Chronic Location: Egg Harbour Township, NJ
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-10016
Conditions: Hepatitis C, Chronic Location: New York, NY
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-13210
Conditions: Hepatitis C, Chronic Location: Syracuse, NY
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-22031
Conditions: Hepatitis C, Chronic Location: Fairfax, VA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-22908
Conditions: Hepatitis C, Chronic Location: Charlottesville, VA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-23249
Conditions: Hepatitis C, Chronic Location: Richmond, VA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-27103
Conditions: Hepatitis C, Chronic Location: Winston-salem, NC
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-27599
Conditions: Hepatitis C, Chronic Location: Chapel Hill, NC
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-28801
Conditions: Hepatitis C, Chronic Location: Asheville, NC
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-30060
Conditions: Hepatitis C, Chronic Location: Marietta, GA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-30308
Conditions: Hepatitis C, Chronic Location: Atlanta, GA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-32256
Conditions: Hepatitis C, Chronic Location: Jacksonville, FL
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-32803
Conditions: Hepatitis C, Chronic Location: Orlando, FL
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-35294
Conditions: Hepatitis C, Chronic Location: Birmingham, AL
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-37660
Conditions: Hepatitis C, Chronic Location: Kingsport, TN
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-38801
Conditions: Hepatitis C, Chronic Location: Tupelo, MS
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-63104
Conditions: Hepatitis C, Chronic Location: St Louis, MO
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-63110
Conditions: Hepatitis C, Chronic Location: St Louis, MO
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-70520
Conditions: Hepatitis C, Chronic Location: Opelousas, LA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-70890
Conditions: Hepatitis C, Chronic Location: Baton Rouge, LA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-73112
Conditions: Hepatitis C, Chronic Location: Oklahoma City, OK
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-78234
Conditions: Hepatitis C, Chronic Location: Fort Sam Houston, TX
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-80045
Conditions: Hepatitis C, Chronic Location: Aurora, CO
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-84132
Conditions: Hepatitis C, Chronic Location: Salt Lake City, UT
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-87131
Conditions: Hepatitis C, Chronic Location: Albuquerque, NM
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90048
Conditions: Hepatitis C, Chronic Location: Los Angeles, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90057
Conditions: Hepatitis C, Chronic Location: Los Angeles, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90505
Conditions: Hepatitis C, Chronic Location: Torrance, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-90822
Conditions: Hepatitis C, Chronic Location: Long Beach, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-92037
Conditions: Hepatitis C, Chronic Location: La Jolla, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-92103
Conditions: Hepatitis C, Chronic Location: San Diego, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-93534
Conditions: Hepatitis C, Chronic Location: Lancaster, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-95816
Conditions: Hepatitis C, Chronic Location: Sacramento, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-95817
Conditions: Hepatitis C, Chronic Location: Sacramento, CA
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-96813
Conditions: Hepatitis C, Chronic Location: Honolulu, HI
- A Study of Combination Therapy With PEGASYS (Peginterferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response. - NCT00623428-97239
Conditions: Hepatitis C, Chronic Location: Portland, OR
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-02115
Conditions: Hepatitis B, Chronic Location: Boston, MA
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-02903
Conditions: Hepatitis B, Chronic Location: Providence, RI
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-06106
Conditions: Hepatitis B, Chronic Location: Hartford, CT
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-10029
Conditions: Hepatitis B, Chronic Location: New York, NY
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-19104
Conditions: Hepatitis B, Chronic Location: Philadelphia, PA
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-21287
Conditions: Hepatitis B, Chronic Location: Baltimore, MD
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-32610
Conditions: Hepatitis B, Chronic Location: Gainesville, FL
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-75390
Conditions: Hepatitis B, Chronic Location: Dallas, TX
- A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection - NCT00423891-94143
Conditions: Hepatitis B, Chronic Location: San Francisco, CA
- A Study of MK7009 in Patients With Chronic Hepatitis C Infection After Participation in Other MK7009 Studies - NCT00943761-14642
Conditions: Chronic Hepatitis C Infection Location: Rochester, NY
- A Study of MK7009 in Patients With Chronic Hepatitis C Infection After Participation in Other MK7009 Studies - NCT00943761-19107
Conditions: Chronic Hepatitis C Infection Location: Philadelphia, PA
- A Study of MK7009 in Patients With Chronic Hepatitis C Infection After Participation in Other MK7009 Studies - NCT00943761-22031
Conditions: Chronic Hepatitis C Infection Location: Fairfax, VA
- A Study of MK7009 in Patients With Chronic Hepatitis C Infection After Participation in Other MK7009 Studies - NCT00943761-28203
Conditions: Chronic Hepatitis C Infection Location: Charlotte, NC
- A Study of MK7009 in Patients With Chronic Hepatitis C Infection After Participation in Other MK7009 Studies - NCT00943761-98103
Conditions: Chronic Hepatitis C Infection Location: Seattle, WA
- A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, Human Location: Baltimore, MD
- A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-20892
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, Human Location: Bethesda, MD
- A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area - NCT00913757-21205
Conditions: Carcinoma, Hepatocellular - Liver Cirrhosis, Alcoholic - Hepatitis, Alcoholic - Hepatitis, Chronic - Hepatitis, Viral, Human Location: Baltimore, MD
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-02905
Conditions: Hepatitis C, Chronic Location: Providence, RI
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-10021
Conditions: Hepatitis C, Chronic Location: New York, NY
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-11030
Conditions: Hepatitis C, Chronic Location: Manhasset, NY
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-21205
Conditions: Hepatitis C, Chronic Location: Baltimore, MD
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-23249
Conditions: Hepatitis C, Chronic Location: Richmond, VA
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-27599
Conditions: Hepatitis C, Chronic Location: Chapel Hill, NC
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-37211
Conditions: Hepatitis C, Chronic Location: Nashville, TN
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-78215
Conditions: Hepatitis C, Chronic Location: San Antonio, TX
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-84132
Conditions: Hepatitis C, Chronic Location: Salt Lake City, UT
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-92118
Conditions: Hepatitis C, Chronic Location: Coronado, CA
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-94115
Conditions: Hepatitis C, Chronic Location: San Francisco, CA
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-95817
Conditions: Hepatitis C, Chronic Location: Sacramento, CA
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols. - NCT00800735-97239
Conditions: Hepatitis C, Chronic Location: Portland, OR
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-03756
Conditions: Hepatitis C, Chronic Location: Lebanon, NH
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-10003
Conditions: Hepatitis C, Chronic Location: New York, NY
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-10021
Conditions: Hepatitis C, Chronic Location: New York, NY
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-10468
Conditions: Hepatitis C, Chronic Location: Bronx, NY
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-19104
Conditions: Hepatitis C, Chronic Location: Philadelphia, PA
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-29204
Conditions: Hepatitis C, Chronic Location: Columbia, SC
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-30309
Conditions: Hepatitis C, Chronic Location: Atlanta, GA
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-34243
Conditions: Hepatitis C, Chronic Location: Sarasota, FL
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-37232
Conditions: Hepatitis C, Chronic Location: Nashville, TN
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-46202
Conditions: Hepatitis C, Chronic Location: Indianapolis, IN
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-60637
Conditions: Hepatitis C, Chronic Location: Chicago, IL
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-64131
Conditions: Hepatitis C, Chronic Location: Kansas City, MO
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-66160
Conditions: Hepatitis C, Chronic Location: Kansas City, KS
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-77030
Conditions: Hepatitis C, Chronic Location: Houston, TX
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-78234
Conditions: Hepatitis C, Chronic Location: Fort Sam Houston, TX
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-87131
Conditions: Hepatitis C, Chronic Location: Albuquerque, NM
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-92037
Conditions: Hepatitis C, Chronic Location: La Jolla, CA
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-96813
Conditions: Hepatitis C, Chronic Location: Honolulu, HI
- A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4 - NCT01057667-96817
Conditions: Hepatitis C, Chronic Location: Honolulu, HI
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-02905
Conditions: Hepatitis C, Chronic Location: Providence, RI
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-07102
Conditions: Hepatitis C, Chronic Location: Newark, NJ
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-10021
Conditions: Hepatitis C, Chronic Location: New York, NY
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-17033
Conditions: Hepatitis C, Chronic Location: Hershey, PA
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-20037
Conditions: Hepatitis C, Chronic Location: Washington, DC
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-21093
Conditions: Hepatitis C, Chronic Location: Lutherville, MD
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-23249
Conditions: Hepatitis C, Chronic Location: Richmond, VA
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-29204
Conditions: Hepatitis C, Chronic Location: Columbia, SC
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-30060
Conditions: Hepatitis C, Chronic Location: Marietta, GA
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-32610
Conditions: Hepatitis C, Chronic Location: Gainesville, FL
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-34243
Conditions: Hepatitis C, Chronic Location: Sarasota, FL
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-35294
Conditions: Hepatitis C, Chronic Location: Birmingham, AL
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-37211
Conditions: Hepatitis C, Chronic Location: Nashville, TN
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-60637
Conditions: Hepatitis C, Chronic Location: Chicago, IL
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-64131
Conditions: Hepatitis C, Chronic Location: Kansas City, MO
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-77030
Conditions: Hepatitis C, Chronic Location: Houston, TX
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-78234
Conditions: Hepatitis C, Chronic Location: Fort Sam Houston, TX
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-92037
Conditions: Hepatitis C, Chronic Location: La Jolla, CA
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-92103
Conditions: Hepatitis C, Chronic Location: San Diego, CA
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-94115
Conditions: Hepatitis C, Chronic Location: San Francisco, CA
- A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4 - NCT00869661-95817
Conditions: Hepatitis C, Chronic Location: Sacramento, CA
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-10029
Conditions: Hepatitis C, Chronic Location: New York, NY
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-11030
Conditions: Hepatitis C, Chronic Location: Manhasset, NY
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-17604
Conditions: Hepatitis C, Chronic Location: Lancaster, PA
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-27599
Conditions: Hepatitis C, Chronic Location: Chapel Hill, NC
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-28801
Conditions: Hepatitis C, Chronic Location: Asheville, NC
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-32256
Conditions: Hepatitis C, Chronic Location: Jacksonville, FL
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-32610
Conditions: Hepatitis C, Chronic Location: Gainesville, FL
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-32809
Conditions: Hepatitis C, Chronic Location: Orlando, FL
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-48109
Conditions: Hepatitis C, Chronic Location: Ann Arbor, MI
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-48202
Conditions: Hepatitis C, Chronic Location: Detroit, MI
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-60148
Conditions: Hepatitis C, Chronic Location: Lombard, IL
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-70112
Conditions: Hepatitis C, Chronic Location: New Orleans, LA
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-78215
Conditions: Hepatitis C, Chronic Location: San Antonio, TX
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-80045
Conditions: Hepatitis C, Chronic Location: Aurora, CO
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-84132
Conditions: Hepatitis C, Chronic Location: Salt Lake City, UT
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-85054
Conditions: Hepatitis C, Chronic Location: Phoenix, AZ
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-90045
Conditions: Hepatitis C, Chronic Location: Los Angeles, CA
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-90822
Conditions: Hepatitis C, Chronic Location: Long Beach, CA
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-92123
Conditions: Hepatitis C, Chronic Location: San Diego, CA
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-92154
Conditions: Hepatitis C, Chronic Location: San Diego, CA
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-95817
Conditions: Hepatitis C, Chronic Location: Sacramento, CA
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-97504
Conditions: Hepatitis C, Chronic Location: Medford, OR
- A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection - NCT00963885-98664
Conditions: Hepatitis C, Chronic Location: Vancouver, WA
- A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults - NCT01038167-
Conditions: Hepatitis C Location: Dallas, TX
- A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy - NCT01058512-
Conditions: Hepatitis C Location: Worcester, MA
- A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy - NCT01058512-01702
Conditions: Hepatitis C Location: Framingham, MA
- A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy - NCT01058512-28304
Conditions: Hepatitis C Location: Fayetteville, NC
- A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy - NCT01058512-32256
Conditions: Hepatitis C Location: Jacksonville, FL
- A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy - NCT01058512-32803
Conditions: Hepatitis C Location: Orlando, FL
- A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy - NCT01058512-33136
Conditions: Hepatitis C Location: Miami, FL
- A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy - NCT01058512-33162
Conditions: Hepatitis C Location: Miami, FL
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-23249
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Richmond, VA
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-32809
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Orlando, FL
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-33607
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Tampa, FL
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-34243
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Sarasota, FL
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-77030A
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Houston, TX
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-77030B
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Houston, TX
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-78215
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: San Antonio, TX
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-85054
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Phoenix, AZ
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-92105
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: San Diego, CA
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-93721
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Fresno, CA
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-94115
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: San Francisco, CA
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-95817
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Sacramento, CA
- Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients - NCT00983060-96817
Conditions: Chronic Hepatitis C Genotype-1 Relapse Location: Honolulu, HI
- Adding Nitazoxanide to Treatment for People With Hepatitis C Virus and HIV Coinfection - NCT00991289-02114
Conditions: HIV Infections - Hepatitis C Virus Location: Boston, MA
- Adding Nitazoxanide to Treatment for People With Hepatitis C Virus and HIV Coinfection - NCT00991289-02115
Conditions: HIV Infections - Hepatitis C Virus Location: Boston, MA
- Adding Nitazoxanide to Treatment for People With Hepatitis C Virus and HIV Coinfection - NCT00991289-02906
Conditions: HIV Infections - Hepatitis C Virus Location: Providence, RI
- Adding Nitazoxanide to Treatment for People With Hepatitis C Virus and HIV Coinfection - NCT00991289-07103
Conditions: HIV Infections - Hepatitis C Virus Location: Newark, NJ
- Adding Nitazoxanide to Treatment for People With Hepatitis C Virus and HIV Coinfection - NCT00991289-19104
Conditions: HIV Infections - Hepatitis C Virus Location: Philadelphia, PA
- Adding Nitazoxanide to Treatment for People With Hepatitis C Virus and HIV Coinfection - NCT00991289-27514
Conditions: HIV Infections - Hepatitis C Virus Location: Chapel Hill, NC
- Adding Nitazoxanide to Treatment for People With Hepatitis C Virus and HIV Coinfection - NCT00991289-35294
Conditions: HIV Infections - Hepatitis C Virus Location: Birmingham, AL
- Adding Nitazoxanide to Treatment for People With Hepatitis C Virus and HIV Coinfection - NCT00991289-44109
Conditions: HIV Infections - Hepatitis C Virus Location: Cleveland, OH
- Adding Nitazoxanide to Treatment for People With Hepatitis C Virus and HIV Coinfection - NCT00991289-90035
Conditions: HIV Infections - Hepatitis C Virus Location: Los Angeles, CA
- Adding Nitazoxanide to Treatment for People With Hepatitis C Virus and HIV Coinfection - NCT00991289-94110
Conditions: HIV Infections - Hepatitis C Virus Location: San Francisco, CA
- Adding Nitazoxanide to Treatment for People With Hepatitis C Virus and HIV Coinfection - NCT00991289-94304
Conditions: HIV Infections - Hepatitis C Virus Location: Palo Alto, CA
- An Integrated Care Model for Improving HCV Patient Outcomes IIR-07-101-3 - NCT00722423-10468
Conditions: Hepatitis C Location: Bronx, NY
- An Integrated Care Model for Improving HCV Patient Outcomes IIR-07-101-3 - NCT00722423-92161
Conditions: Hepatitis C Location: San Diego, CA
- An Integrated Care Model for Improving HCV Patient Outcomes IIR-07-101-3 - NCT00722423-94304
Conditions: Hepatitis C Location: Palo Alto, CA
- Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C - NCT00930995-95661
Conditions: Hepatitis C Location: Roseville, CA
- Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C - NCT00930995-95825
Conditions: Hepatitis C Location: Sacramento, CA
- Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection - NCT00239733-10021
Conditions: Thrombocytopenia - Hepatitis C - HIV Infections Location: New York, NY
- Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection - NCT00395018-14642
Conditions: Hepatitis B, Chronic Location: Rochester, NY
- Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection - NCT00395018-55905
Conditions: Hepatitis B, Chronic Location: Rochester, MN
- Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection - NCT00395018-60611
Conditions: Hepatitis B, Chronic Location: Chicago, IL
- Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection - NCT00395018-68198
Conditions: Hepatitis B, Chronic Location: Omaha, NE
- Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection - NCT00395018-70112
Conditions: Hepatitis B, Chronic Location: New Orleans, LA
- Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection - NCT00395018-75246
Conditions: Hepatitis B, Chronic Location: Dallas, TX
- Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection - NCT00395018-77030
Conditions: Hepatitis B, Chronic Location: Houston, TX
- Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis - NCT00854087-92103
Conditions: Chronic Hepatitis C Infection Location: San Diego, CA
- Baclofen to Reduce Alcohol Use in Veterans With HCV - NCT01008280-55417
Conditions: Hepatitis C - Alcohol Use Disorders Location: Minneapolis, MN
- Baclofen to Reduce Alcohol Use in Veterans With HCV - NCT01008280-90822
Conditions: Hepatitis C - Alcohol Use Disorders Location: Long Beach, CA
- Baclofen to Reduce Alcohol Use in Veterans With HCV - NCT01008280-97201
Conditions: Hepatitis C - Alcohol Use Disorders Location: Portland, OR
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-07102
Conditions: Hepatitis C Virus - HIV Infections Location: Newark, NJ
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-21287
Conditions: Hepatitis C Virus - HIV Infections Location: Baltimore, MD
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-75204
Conditions: Hepatitis C Virus - HIV Infections Location: Dallas, TX
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus - NCT00503347-92663
Conditions: Hepatitis C Virus - HIV Infections Location: Newport Beach, CA
- Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM1) - NCT01023035-02905
Conditions: Hepatitis C, Chronic Location: Providence, RI
- Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM1) - NCT01023035-17604
Conditions: Hepatitis C, Chronic Location: Lancaster, PA
- Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM1) - NCT01023035-22306
Conditions: Hepatitis C, Chronic Location: Alexandria, VA
- Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM1) - NCT01023035-28677
Conditions: Hepatitis C, Chronic Location: Statesville, NC
- Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM1) - NCT01023035-33414
Conditions: Hepatitis C, Chronic Location: Wellington, FL
- Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM1) - NCT01023035-38138
Conditions: Hepatitis C, Chronic Location: Germantown, TN
- Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM1) - NCT01023035-64131
Conditions: Hepatitis C, Chronic Location: Kansas City, MO
- Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM1) - NCT01023035-78215
Conditions: Hepatitis C, Chronic Location: San Antonio, TX
- Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM1) - NCT01023035-93301
Conditions: Hepatitis C, Chronic Location: Bakersfield, CA
- Cell Bound Complement Activation Proteins as Markers of Liver Injury - NCT01025531-15213
Conditions: Hepatitis C Location: Pittsburgh, PA
- Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects - NCT00136214-02215
Conditions: Hepatitis C Location: Boston, MA
- Characterization of Clonal B Cell Populations in HCV Infection - NCT00435201-10065
Conditions: Hepatitis C Location: New York, NY
- Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390 - NCT00996216-96817
Conditions: Hepatitis C - Thrombocytopaenia Location: Honolulu, HI
- Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children - NCT00677183-53226
Conditions: Non-Alcoholic Steatohepatitis Location: Milwaukee, WI
- Dose-Ranging Study of PSI-7977 in Combination With SOC in Treatment Naïve GT 1 HCV Patients - NCT01054729-32803
Conditions: Hepatitis C Location: Orlando, FL
- Dose-Ranging Study of PSI-7977 in Combination With SOC in Treatment Naïve GT 1 HCV Patients - NCT01054729-78215
Conditions: Hepatitis C Location: San Antonio, TX
- Dose-Ranging Study of PSI-7977 in Combination With SOC in Treatment Naïve GT 1 HCV Patients - NCT01054729-94115
Conditions: Hepatitis C Location: San Francisco, CA
- Dose-Ranging Study of PSI-7977 in Combination With SOC in Treatment Naïve GT 1 HCV Patients - NCT01054729-98101
Conditions: Hepatitis C Location: Seattle, WA
- Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment - NCT01052701-21287
Conditions: Hepatitis C Location: Baltimore, MD
- Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity - NCT00878592-15213
Conditions: Post Liver Transplantation Weight Gain - Post Liver Transplantation Obesity - Nonalcoholic Steatohepatitis Location: Pittsburgh, PA
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-01107
Conditions: Hepatitis B Infection Location: Springfield, MA
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-02115
Conditions: Hepatitis B Infection Location: Boston, MA
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-02905
Conditions: Hepatitis B Infection Location: Providence, RI
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-10003
Conditions: Hepatitis B Infection Location: New York, NY
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-10010
Conditions: Hepatitis B Infection Location: New York, NY
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-10701
Conditions: Hepatitis B Infection Location: Yonkers, NY
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-19141
Conditions: Hepatitis B Infection Location: Philadelphia, PA
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-20740
Conditions: Hepatitis B Infection Location: College Park, MD
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-33136
Conditions: Hepatitis B Infection Location: Miami, FL
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-33144
Conditions: Hepatitis B Infection Location: Miami, FL
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-36116
Conditions: Hepatitis B Infection Location: Montgomery, AL
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-60612
Conditions: Hepatitis B Infection Location: Chicago, IL
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-60637
Conditions: Hepatitis B Infection Location: Chicago, IL
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-70121
Conditions: Hepatitis B Infection Location: New Orleans, LA
- Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection - NCT00371150-78215
Conditions: Hepatitis B Infection Location: San Antonio, TX
- Effective Treatment of Hepatitis C in Substance Users - NCT00633243-06519
Conditions: Hepatitis C - Opiate Dependence Location: New Haven, CT
- Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV - NCT00545558-23298
Conditions: Hepatitis C - HIV Infections Location: Richmond, VA
- Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV - NCT00545558-45229
Conditions: Hepatitis C - HIV Infections Location: Cincinnati, OH
- Effects of HIV and Hepatitis C Virus on the Brain - NCT00494936-10029
Conditions: HIV Infections - Hepatitis C Location: New York, NY
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-10016
Conditions: Acute On Chronic Hepatitis Location: New York, NY
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-10032
Conditions: Acute On Chronic Hepatitis Location: New York, NY
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-14642
Conditions: Acute On Chronic Hepatitis Location: Rochester, NY
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-19104
Conditions: Acute On Chronic Hepatitis Location: Philadelphia, PA
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-19140
Conditions: Acute On Chronic Hepatitis Location: Philadelphia, PA
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-22908
Conditions: Acute On Chronic Hepatitis Location: Charlottesville, VA
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-35294
Conditions: Acute On Chronic Hepatitis Location: Birmingham, AL
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-45267
Conditions: Acute On Chronic Hepatitis Location: Cincinnati, OH
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-46202
Conditions: Acute On Chronic Hepatitis Location: Indianapolis, IN
- Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (Stabilization in Liver Disease) - NCT00973817-48109
Conditions: Acute On Chronic Hepatitis Location: Ann Arbor, MI
|
|
|
|
|
Didn't find what you were looking for? Try these alternatives:
Become A Member: To be notified of upcoming clinical trials in your
area please create a free member account.
Browse Studies: If you would like to browse all featured clinical trials
please Browse Studies.
Message Board: Join the discussion in our Health
and Clinical Trials Message Board.
|
|
|